Open Federal Grants · Food and Drug Administration
Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed
Food and Drug Administration · Opportunity FOR-FD-24-007 · Awards up to $300,000
Eligibility
Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submissi
Eligibility text quoted from the official Grants.gov listing.
About This Opportunity
The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereo chemically controlled synthesis and biological activity assessment using in vitro and animal models. The proposed studies will focus on 1) synthesis of each diastereomer of LEQVIO (Inclisiran) in stereo chemica …
Description from the official Grants.gov listing — read the complete notice, including any updates, on Grants.gov before applying.
More Open Grants From FDA
Browse Open Grants
By who can apply:
By agency:
By closing month:
Every grant listed here comes from Grants.gov, the official U.S. government database. Award amounts and deadlines can change — verify the details on the official listing before you apply. GrantRound is not affiliated with the U.S. government.